Lean mass is not a synonym for strength, and a change in one performance test is not a general athletic benefit. Growth-hormone discussions often overlook both distinctions.
A randomized trial in 96 recreational athletes measured body composition and several performance outcomes. Increased lean mass was linked to extracellular water, while the performance findings differed by test. The authors also said the study was too small to establish safety. This is a much narrower result than a claim that HGH broadly builds functional muscle.
Read each endpoint separately
If a study measures strength, endurance, jumping and sprint capacity, readers should not replace the full result with whichever measure looks most favorable. The other tests remain part of the evidence.
The distinction between lean mass and tissue function matters because a body-composition category can contain more than the change a reader imagines. A larger number in that category does not by itself reveal what tissue changed or whether a useful task became easier.
Duration is another boundary. A short trial cannot establish lasting benefit, long-term safety or the result of a different exposure pattern. Nor does describing a study regimen make it appropriate to reproduce.
This article does not offer a performance-enhancement plan. It explains why a physiological effect should not be turned into a broad recommendation, particularly when safety and durability remain unresolved.
An athlete or recreational lifter who suspects a genuine endocrine problem can discuss symptoms and diagnostic testing with a qualified clinician. That is different from using a research hormone to pursue a laboratory or body-composition target.
The careful reading is to keep the measurement, time window and population attached to the result. A paper can show a real effect while still failing to justify the larger claim circulating online. Losing those distinctions turns a scientific finding into an advertisement the study did not test.